A Real-World, Prospective, Non-interventional Study of Adults with T2D Switching to IDegAsp from Glargine U100 or U300 in Japan.

Diabetes Ther · 2021 · PMC8385001 · PMID 34304385

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

During the study, there were trends toward a reduction in overall and nocturnal non-severe hypoglycaemia, which did not reach statistical significance for either endpoint.

also in 111,027 other papers

a numerical trendno p-value reported

Over 26 weeks, switching to IDegAsp from glargine U100 or U300 was associated with significant reductions in the daily total and basal insulin dose; furthermore, numerically fewer patients required prandial insulin injections at EOS compared with baseline, with a numerical trend toward a lower daily prandial insulin dose after initiating IDegAsp.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.